Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of once-weekly PF-08653944 in Chinese adults with overweight or obesity
CTR20263227Phase 3Active
- Sponsor
- Pfizer
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of PF-08653944 in Overweight, obesity, sponsored by Pfizer. Started Aug 2026; status: active.
02
Drugs
PF-08653944
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20263227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263227.